TH86242A - Indole-3-il-carbonyl-spiro-piperidine derivative that is V1a receptor antagonist. - Google Patents

Abstract

DC60 (22/09/49) This invention is concerned with the derivative of indol-3-yl-carbonyl-spiro-piperidine, which acts as a V1a receptor antigoneist and is denoted by the formula l : (chemical formula) (l), in which the main group spiro-piperidine A and the residuals R1, R2 and R3 are as defined herein. The invention is also concerned with pharmaceutical mixtures containing such compounds, their use in pharmaceuticals for the treatment of dysmenorrhea, hypertension, chronic heart failure, vasopressin dysfunction, cirrhosis, renal syndromes, obsessive-compulsive disorders, anxiety and depression disorders, and methods of their preparation. This invention relates to the derivative of indol-3-yl-carbonyl-spiro-piperidine, which acts as a Vla receptor antigone and is denoted by the formula l: (chemical formula) (l), in which the main group spiro-piperidine A and the residuals R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical mixtures containing this compound, their use in pharmaceuticals for the treatment of menstrual pain, hypertension, chronic heart failure, vasopressin dysfunction, cirrhosis, renal syndromes, obsessive-compulsive disorders, anxiety and depression disorders, and methods of their preparation.

Claims (43)

1. A compound with the general formula (l) (chemical formula) (l) in which A can be chosen from the following groups (a), (b), (c), (d), (e), (f), (g), and (h): (chemical formula) (a) (chemical formula) (b) (chemical formula) (c) (chemical formula) (d) (chemical formula) (e) (chemical formula) (f) (chemical formula) (g) (chemical formula) (h) in which (a) the dashed line is nothing or a double bond; R1 is H, or is C1-6-alkyl which may be chosen to be replaced by CN, or is an aryl, heteroaryl with 5 or 6 members, or sulfonylaryl which may be chosen to be replaced by one or more groups B; Or -(CH2)m-Ra, where Ra is: CN, ORi, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 7 members (3 of 261 compounds), aryl, or heteroaryl with 5 or 6 members which may be selectively replaced by one or more B groups; Or -(CH2)n-(CO)-Rb or -(CH2)-(SO2)-Rb, where Rb is: C1-6-alkyl, C1-6-alkoxy, C3-6-cycloalkyl, -(CH2)m-NRiiiRiv, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 4 to 7 members, aryl, or heteroaryl with 5 or 6 members which may be selectively replaced by one or more B groups; or R1 and R3 together with the indole ring to which they are attached, forming A heterocycloalkyl with 5 or 6 members which can be replaced by =O, C(O)O-C1-6-alkyl, or C1-6-alkyl; R2 is one or more groups of H, OH, halo, CN, nitro, C1-6-alkyl which may be selectively replaced by NRiiiRiv, C1-6-alkoxy, -O-CH2-C2-6-alkenyl, benzyloxy, or two R2 groups may form an oxo or dioxo bridge with the indole ring to which they are attached; R3 is H, or is halo, or is -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii, -(CH2)n-NRiiiRiv. A heterocycloalkyl with 5 or 6 members that may be selectively substituted by C1-6-alkyl, or C1-6-alkyl or aryl that may be selectively substituted by halo, -O(CO)-C1-6-alkyl, or by -NH(CO)Rd, where Rd is a C1-6-alkyl that may be selectively substituted by halo or nitro, or Rd is an aryl or heteroaryl with 5 or 6 members, that may be selectively substituted by halo, nitro, C1-6-alkyl, or C1-6-haloalkyl; R4 is one or more groups of H, halo, C1-6-alkyl, or C1-6-alkoxy. Which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H, C1-6-alkyl or aryl; R6 is H or C1-6-alkyl; R7 is H or -SO2-Rc, where Rc is C1-6-alkyl or aryl; R8 is H or C1-6-alkyl; X is CH2 or C=O; B is halo, CN, NRiRii, C1-6-alkyl which may be selectively replaced by CN, halo or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -C(O)NRiRii. -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiRii, (CRiiiRiv)n-phenyl, or (CRiiiRiv)n-heteroaryl with 5 or 6 members, where a phenyl or heteroaryl moity with 5 or 6 members may be selectively replaced by one or more selectable substituents from the group consisting of halo, CN, NRiRii, C1-6-alkyl which may be selectively replaced by CN, halo, or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -C(O)-NRiRii, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiRii; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -C(O)-NRiiiRiv, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiiiRiv or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmaceutically acceptable salts of these. 2. A compound with the formula (l) according to claim 1, in which A is selectable from (a), (b), (c), (d), (e), (f), (g) and (h), and in which R1 is H, or is a C1-6-alkyl which may be selectable to be substituted by CN, or is an aryl, a 5 or 6 member heteroaryl, or a sulfonylaryl which may be selectable to be substituted by one or more B groups; or is -(CH2)m-Ra, in which Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, a 3 to 7 member heterocycloalkyl, an aryl, or a 5 or 6 member heteroaryl which may be selectable to be substituted by one or more B groups; Or -(CH2)n-(CO)-Rb or -(CH2)-(SO2)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a heterocycloalkyl with 4 to 7 members, an aryl, or a heteroaryl with 5 or 6 members which may be selectively replaced by one or more B groups; or R1 and R3 together with the indole ring to which they are attached, forming A heterocycloalkyl with 5 or 6 members that can be replaced by =O, C(O)O-C1-6-alkyl, or C1-6-alkyl; R2 is one or more groups of H, OH, halo, C1-6-alkyl which may be selectively replaced by NRiiiRiv, C1-6-alkoxy; R3 is H, or is halo, or is -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii, -(CH2)n-NRiiiRiv, a heterocycloalkyl with 5 or 6 members that can be selectively replaced by C1-6-alkyl, or is C1-6-alkyl, or aryl which may be selectively replaced by halo; R4 is one or more groups of H. , halo, or C1-6-alkoxy which may be selectively replaced by OH, or R4, two groups may form oxo or dioxo bridges with the phenyl ring to which they are attached; R5 is H or aryl; R6 is H; R7 is H or -SO2-Re, where Re is C1-6-alkyl or aryl; R8 is H or C1-6-alkyl; X is CH2 or C=O; B is halo, CN, NH2, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl Phenyl may be selectively replaced by one or more substituents from a selection of halo, C1-6-alkyl groups which may be replaced by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -C(O)-NRiiiRiv, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiiiRiv or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 3. A compound with the general formula (l) according to claim 1 or 2, in which A is selectable from the following groups (a), (b), (c), (d) or (e), and R1 is H, or is a C1-6-alkyl which may be selectable to be substituted by CN, or is an aryl, a 5 or 6 member heteroaryl, or a sulfonylaryl which may be selectable to be substituted by one or more groups B; or is -(CH2)m-Ra, where Ra is: CN, ORi, NRiRii, C3-6-cycloalkyl, a 3 to 7 member heterocycloalkyl, an aryl, or a 5 or 6 member heteroaryl which may be selectable to be substituted by one or more groups B; Or -(CH2)n-(CO)-Rb or -(CH2)-(SO2)-Rb, where Rb is: C1-6-alkyl, C1-6-alkoxy, C3-6-cycloalkyl, -(CH2)m-NRiiiRiv, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 4 to 7 members, aryl, or heteroaryl with 5 or 6 members which may be chosen to be replaced by one or more B groups; or R1 and R3 together with the indole ring to which they are attached, forming A heterocyclocycloalkyl with 5 or 6 members that may be substituted by (CO); R2 is one or more groups of H, OH, halo, CN, nitro, C1-6-alkyl that may be selectively substituted by NRiiiRiv, C1-6-alkoxy, -O-CH2-C2-6-alkenyl, benzyloxy, or two R2 groups may form an oxo or dioxo bridge with the indole ring to which they are attached; R3 is H, or is halo, or is -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii, -(CH2)n-NRiiiRiv, a heterocyclocycloalkyl with 5 or 6 members that may be selectively substituted by C1-6-alkyl. Or, it is C1-6-alkyl, or aryl, which may be selectively replaced by halo, -O(CO)-C1-6-alkyl, or by -NH(CO)Rd, where Rd is the selectively replaced C1-6-alkyl. Substituted by halo or nitro, or Rd is an aryl or heteroaryl with 5 or 6 members, which may be selectively substituted by a halo, nitro, C1-6-alkyl, or C1-6-haloalkyl; R4 is one or more groups of H, halo, C1-6-alkyl, or C1-6-alkoxy, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring to which they are attached; R5 is H, C1-6-alkyl, or aryl; R6 is H or C1-6-alkyl; R7 is H or -SO2-Re, where Re is C1-6-alkyl or aryl; B is a halo, CN, NRiRii, C1-6-alkyl that may be selectively substituted by CN, halo, or... C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -C(O)NRiRii, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiRii, (CRiiiRiv)n-phenyl or (CRiiiRiv)n-heteroaryl with 5 or 6 members, where a phenyl or heteroaryl moity with 5 or 6 members may be selectively replaced by one or more selectable substituents from the group consisting of halo, CN, NRiRii, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -C(O)-NRiRii, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiRii; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -C(O)-NRiiiRiv, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl or -S(O)2-NRiiiRiv; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmaceutically acceptable salts of these. 4. A compound with the general formula (l) according to any of the claims 1 through 3, in which A is selectable from the following substituents (a), (b), (c), (d) or (e), and R1 is H or , C1-6-alkyl which may be substituted by CN or , C1-6-alkoxy or , aryl or , 5 or 6 member heteroaryl or , sulfonylaryl or , -(CH2)m-Ra, where Ra is C3-6-cycloalkyl, 5 to 6 member heterocycloalkyl, aryl, or 5 or 6 member heteroaryl which may be substituted by one or more selectable substituents. A group consisting of halo, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl, and phenyl, which may be selectively replaced by halo, C1-6-alkyl, C1-6-haloalkyl, or C1-6-alkoxy, -(CH2)m-NR'R'', or , -(CH2)n-(CO)-Rb, where Rb is an aryl or heterocycloalkyl with 5 or 6 members; R2 is one or more groups of H, halo, CN, nitro, C1-6-alkyl, C1-6-alkoxy, -O-CH2-C2-6-alkenyl, benzyloxy, or two R2 groups, may be constructed as oxo or A dioxobridge is attached to an indole ring to which they are bound; R3 is H or , halo or , -(CO)-Rc, where Rc is C1-6-alkyl, a 5 or 6-membered heterocycloalkyl which may be chosen to be replaced by C1-6-alkyl, or Rc is -(CH2)n -NR'R'' or , C1-6-alkyl or aryl which may be chosen to be replaced by -O(CO)-C1-6-alkyl, or -NH(CO)Rd, where Rd is a C1-6-alkyl which may be selectively replaced by a halo or nitro, or Rd is a 5- or 6-membered aryl or heteroaryl which may be selectively replaced by a halo, nitro, C1-6-alkyl, or C1-6-haloalkyl; R4 is one or more groups of H, halo, C1-6-alkyl, or C1-6-alkoxy, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are bound to; R5 is H, C1-6-alkyl, or aryl; R6 is H or C1-6-alkyl; R7 is H or -SO2-Re, where Rc is C1-6-alkyl or aryl; R' and R'' can be independently selected from H, C1-6-alkyl, or -(CO)O-C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmaceutically acceptable salts of these. 5. A compound with the formula (l-a) according to one of the claims 1 through 4: (chemical formula) (l-a), where the dashed line means nothing or a double bond, and R1 through R6 is as defined in one of the claims 1 through 4. 6. Compounds with the formula (l-a) according to claim 5, where dashed lines represent nothing or a double bond; R1 is H, or is C1-6-alkyl which may be selectively substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 6 members, aryl, or heteroaryl with 5 or 6 members which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a 6-membered heterocycloalkyl, aryl, or a 5 or 6-membered heteroaryl which may be selectively replaced by one or more B groups; R2 is one or more groups of H, halo, C1-6-alkyl; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; R5 is H; R6 is H; B is halo, CN, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively substituted by one or more substituents from a selection of halo, C1-6-alkyl groups which may be substituted by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -S(O)2-C1-6-alkyl, or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 7. Compounds with the formula (l-a) according to claim 5 or 6 in which: dashed line means nothing or a double bond; R1 is H, or -(CH2)m-Ra, where Ra is an aryl which may be selectively substituted by one or more substituents of a group consisting of: halo, -CN, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl and phenyl which may be selectively substituted by halo, C1-6-alkyl, C1-6-haloalkyl or C1-6-alkoxy; R2 is H or halo; R3 is H or C1-6-alkyl; and R4, R5 and R6 are H; m is 1 through 6; including pharmacologically acceptable salts of these. 8. Any compound with the formula (l-a) according to one of the claims 5 through 7, which can be selected from the group consisting of: 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]spiro[indine-1,4'-piperidine] ; 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]-2,3-dihydrospiro[indine-1,4'-piperidine] ; 1'-[(1-benzyl-1H-indol-3-yl)carbonyl]spiro[indine-1,4'-piperidine] ; 1'-[(2-methyl-1H-indol-3-il)carbonyl]spiro[indine-1,4'-piperidine]; 1'-[(6-chloro-1H-indol-3-il)carbonyl]spiro[indine-1,4'-piperidine]; and 1'-[(6-chloro-1H-indol-3-il)carbonyl]-2,3-dihydrospiro[indine-1,4'-piperidine] 9. A compound with the formula (l-b) according to one of the claims 1 through 4 (chemical formula) (l-b), where R1, R2, R3, R4, R6 and R7 are as defined in one of the claims 1 through 4. 10. Compounds with the formula (l-b) according to claim 9, where R1 is H, or is a C1-6-alkyl which may be selectively substituted by CN, or is a sulfonylaryl, or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 6 members, aryl, or heteroaryl with 5 or 6 members which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a 5 to 6 member heterocycloalkyl, aryl, or a 5 or 6 member heteroaryl which may be selectively replaced by one or more B groups; R2 is one or more groups of H, halo, C1-6-alkyl; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; R6 is H; R7 is H or -SO2-Re, where Re is C1-6 alkyl or aryl; B is halo, CN, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively substituted by one or more substituents from a selection of halo, C1-6-alkyl groups which may be substituted by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)-C1-6-alkyl, -S(O)2-C1-6-alkyl, or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 11. Compounds with the formula (l-b) according to claim 9 or 10, where R1 is H, or is -(CH2)m-Ra, where Ra is an aryl, or a heteroaryl of 5 or 6 members which may be selectively substituted by one or more substituents chosen from the group consisting of: halo, -CN, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl and phenyls which may be selectively replaced by halo, C1-6-haloalkyl or C1-6-alkoxy, or i.e. -(CH2)m-NRiRii, or i.e. -(CH2)n-(CO)-Rb, where Rb is aryl, or heterocycloalkyls with 5 or 6 members which may be selectively replaced by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is NRiRii, R2 is H or halo; R3 is H or C1-6-alkyl; R4 is H or halo; R6 is H; R7 is H or -SO2-Rc, where Rc is C1-6-alkyl or aryl; B is halo, NH2, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively replaced by one or more substituents from a selection of halo, C1-6-alkyl groups which may be selectively replaced by CN or halo, C1-6-alkoxy; Ri, Rii independently selectable from H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 12. Any compound with the formula (l-b) according to one of the claims 9 through 11, which can be selected from the group consisting of: 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]-1-(methensulfonyl)-1,2-dihydrospiro[indole-3,4'-piperidine]; 1'-{[6-chloro-1-(3-fluorobenzoyl)-1H-indol-3-yl]carbonyl}-1,2-dihydrospiro[indole-3,4'-piperidine]; 1'-{[6-chloro-1-(2-fluorobenzoyl)-1H-indol-3-il]carbonyl}-1,2-dihydrospiro[indol-3,4'-piperidine] ; 1'-{[6-chloro-1-(3,5-difluorobenzoyl)-1H-indol-3-il]carbonyl}-1,2-dihydrospiro[indol-3,4'-piperidine] ; 1'-{[6-chloro-1-(2,3-difluorobenzoyl)-1H-indol-3-il]carbonyl}-1,2-dihydrospiro[indol-3,4'-piperidine] ; 1'-({6-chloro-1-[(3,5-difluorophenyl)sulfonyl]-1H-indol-3-il}carbonyl)-1,2-dihydrospiro[indol-3,4'-piperidin] ; 2-[6-chloro-3-(1,2-dihydro-1'H-spiro[indol-3,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-1-(3,5-difluorophenyl)ethanone ; 2-[6-chloro-3-(1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-ilcarbonyl)-1H-indole-1-il]-1-(3,4-difluorophenyl)ethanone ; 2-[6-chloro-3-(1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-ilcarbonyl)-1H-indole-1-il]-1-(2-fluorophenyl)ethanone ; 2-[6-chloro-3-(1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-ilcarbonyl)-1H-indole-1-il]-N,N-diethylethanamine; and 1'-{[6-chloro-1-(pyridin-2-ilmethyl)-1H-indole-3-il]carbonyl}-1,2-dihydrospiro[indole-3,4'-piperidin] 13. A compound with the formula (l-c) according to one of the claims 1 through 4: (chemical formula) (l-c) where R1 through R4 is as defined in one of the claims 1 through 4. 14. Compounds with the formula (l-c) according to claim 13, where R1 is H, or is a C1-6-alkyl which may be selectively substituted by CN, or is an aryl, a 5 or 6-membered heteroaryl, or a sulfonylaryl which may be selectively substituted by one or more B groups; or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, a 4 to 7-membered heterocycloalkyl, an aryl, or a 5 or 6-membered heteroaryl which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a heterocycloalkyl with 4 or 7 members, an aryl, or a heteroaryl with 5 or 6 members which may be selectively replaced by one or more B groups; or R1 and R3 together with the indole ring to which they are attached, forming A heterocycloalkyl with 5 or 6 members that can be replaced by =O; R2 is one or more groups of H, halo, C1-6-alkyl that may be chosen to be replaced by NRiiiRiv, C1-6-alkoxy; R3 is H, or C1-6-alkyl, or is halo, or is -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii, -(CH2)n-NRiiiRiv, a heterocycloalkyl with 5 or 6 members that may be chosen to be replaced by C1-6-alkyl; R4 is one or more groups of H, halo, or C1-6-alkoxy. Which may be selectively replaced by OH, or R4, two groups may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; B is halo, NH2, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl Phenyl may be selectively replaced by one or more substituents from a selection of halo, C1-6-alkyl groups which may be selectively replaced by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -C(O)-NRiiiRiv, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiiiRiv; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 15. Compounds with the formula (l-c) according to claims 13 to 14, which may be selected from the group containing: 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one; 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]-4-chloro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-6-methoxy-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-5-methoxy-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-7-chloro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(6-chloro-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(6-chloro-1H-indol-3-il)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il) carbonyl]-N,N-dimethyl-1H-indole-2-carboxamide ; tert-butyl {2-[({6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin-1'-il)carbonyl]-1H-indole-2-il}carbonyl)amino]ethyl}-methylcarbamate ; 6-chloro-N,N-diethyl-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)carbonyl)-1H-indole-2-carboxamide ; 1'-{[6-chloro-2-(piperidin-1-ylcarbonyl)-1H-indole-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(1-benzyl-2-methyl-1H-indole-3-il)carbonyl]-7H-spirofuro[3,4-b][1,3]-benzodioxol-5,4'-piperidin]-7-one ; 3-{6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indole-1-il}propanenitrile ; {6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indole-1-il}acetamide ; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-6-(2-hydroxyethoxy)-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-3H-spiro[furo[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3,5-difluorophenyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3-fluorobenzyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(3-fluorophenyl)-2-oxoethyl]-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(2,5-difluorophenyl)-2-oxoethyl]-1H-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3-fluorobenzyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(3-fluorophenyl)-2-oxoethyl]-1H-indol-3-yl}carbonyl)- 5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 5-bromo-1'-{[6-chloro-1-(3,5-difluorobenzyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 5-bromo-1'-{[6-chloro-1-(3-fluorobenzyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 5-bromo-1'-({6-chloro-1-[2-(3-fluorophenyl)-2-oxoethyl]-1H-indol-3-il}-carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(2-fluorophenyl)-2-oxoethyl]-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(3,4-difluorophenyl)-2-oxoethyl]-1H-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(3-fluorophenyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(2-oxo-2-piperidin-1-ylethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(2-morpholin-4-yl-2-oxoethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 2-{6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)-carbonyl]-1H-indole-1-il}-N,N-dimethylacetamide ; 2-{6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)-carbonyl]-1H-indole-1-il}-N,N-diethylacetamide ; 1'-{[6-chloro-1-(piperidin-1-il carbonyl)-1H-indole-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; tert-butyl {6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin-1'-il)-carbonyl]-1H-indole-1-il}acetate ; 1'-[(6-chloro-1-pyridin-2-il-1H-indole-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(6-chloro-1-pyridin-2-yl-1H-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(2-methylpyridin-4-yl)methyl]-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(6-chloropyridin-3-yl)methyl]-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(3-chloro-6-methylpyridazin-4-yl)methyl]-1H-indol-3-yl}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyridin-4-ilmethyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(2-pyridin-4-ilmethyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyridin-4-ilmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(2-oxo-2-pyridin-2-ylethyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)-2-oxoethyl]-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyridin-2-ilmethyl)-1H-indol-3-il]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 2-{6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indol-1-il}-N,N-dimethylacetamide ; 1'-({6-chloro-1-[2-(dimethylamino)ethyl]-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyridin-3-ylmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyrazin-2-ylmethyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyrimidin-5-ilmethyl)-1H-indol-3-il]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 3-{6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indol-1-il}propanenitrile ; tert-butyl {6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indole-1-il}acetate ; 1'-{[6-chloro-1-(2-morpholin-4-il-2-oxoethyl)-1H-indole-3-il]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({1-[(4-benzylmorpholin-2-yl)methyl]-6-chloro-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(5-methylisoxazol-3-yl)methyl]-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[2-(4-methylpiperazine-1-yl)-2-oxoethyl]-1H-indol-3-yl}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[6-chloro-1-(pyridin-2-ylmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(5-cyclopropyl-2-methyl-1,3-oxazol-4-yl)methyl]-1H-indol-3-yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1H-indol-3-yl}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(3-methyl isoxazol-5-yl)methyl]-1H-indol-3-yl}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-1H-indol-3-yl}carbonyl)- 5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(3,5-dimethyl-oxaxol-4-yl)methyl]-1H-indol-3-yl}carbonyl)- 5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(2,5-dimethyl-1,3-oxaxol-4-yl)methyl]-1H-indol-3-yl}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(3-fluorooxytan-3-yl)methyl]-1H-indol-3-yl}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-1-[(3-fluorooxytan-3-yl)methyl]-1H-indol-3-yl}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-[(6-chloro-1-{[1-(methoxymethyl)-cyclopropyl]methyl}-1H-indole-3-yl)-carbonyl]-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; [1-({6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)carbonyl]-1H-indole-1-yl}methyl)cyclopropyl]acetamide ; 1'-[(6-chloro-1-{[1-(methoxymethyl)-cyclopropyl]methyl}-1H-indol-3-il)-carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-({6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)-carbonyl]-1H-indol-1-il}methyl)cyclopropyl]acetonitrile ; 1'-({6-chloro-1-[2-(tetrahydro-2H-pyran-4-il)ethyl]-1H-indol-3-il}-carbonyl)-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one hydrochloride; 1'-({6-chloro-1-[2-(tetrahydro-2H-pyran-4-il)ethyl]-1H-indol-3-il}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one; tert-butyl 2-({6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indole-1-il}methyl)morpholine-4-carboxylate ; tert-butyl 2-{6-chloro-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)carbonyl]-1H-indole-1-il}methyl)morpholine-4-carboxylate ; 1'-{[6-chloro-1-(morfolin-2-ilmethyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one dihydrochloride; 1'-{[6-chloro-1-(morfolin-2-ilmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one dihydrochloride; 2-{6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'- il)carbonyl]-1H-indol-1-il}-acetamide ; 2-{6-chloro-3-[(5-fluoro-3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'- il)carbonyl]-1H-indol-1-il}-N-methylacetamide ; 1'-{[6-chloro-1-(2-oxo-2-piperazine-1-ylethyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; 1'-{[1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}-5-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; N,N-diethyl-2-{3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)-carbonyl]-1H-indol-1-il}-N-methylacetamide; and 2-{6-chloro-5-methyl-3-[(3-oxo-1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-il)-carbonyl]-1H-indol-1-il}-N,N-dimethylacetamide 16. A compound with the formula (l-d) according to one of the claims 1 through 4 (chemical formula) (l-d), where R1 through R5 are as defined in one of the claims 1 through 4. 17. Compounds with the formula (l-d) according to claim 16, where R1 is H, or is a C1-6-alkyl which may be selectively substituted by CN, or is an aryl, a 5 or 6-membered heteroaryl, or a sulfonylaryl which may be selectively substituted by one or more B groups; or is -(CH2)m-Ra where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, a 3 to 7-membered heterocycloalkyl, an aryl, or a 5 or 6-membered heteroaryl which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a heterocycloalkyl with 4 or 7 members, an aryl, or a heteroaryl with 5 or 6 members which may be selectively replaced by one or more B groups; or R1 and R3 together with the indole ring to which they are attached, forming A heterocycloalkyl with 5 or 6 members which can be replaced by C(O)O-C1-6-alkyl or C1-6-alkyl; R2 is one or more groups of H, halo, C1-6-alkyl, C1-6-alkoxy; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is C1-6-alkyl, or -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; R5 is H or aryl; B is halo, NH2, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively replaced by one or more substituents from a selection of halo, C1-6-alkyl groups which may be replaced by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -C(O)-NRiiiRiv, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl, -S(O)2-NRiiiRiv or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 18. Compounds with the formula (l-d) according to claim 16 or 17, which may be selected from the group consisting of: 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(2-methyl-1H-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[2-methyl-1-(phenylsulfonyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[1-(cyclohexylmethyl)-2-methyl-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[1-(3-fluorobenzyl)-2-methyl-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({2-methyl-1-[2-(trifluoromethoxy)benzyl]-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[1-(3,5-dimethylbenzyl)-2-methyl-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; Methyl 4-{[2-methyl-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]methyl}benzoate; 4-{[2-methyl-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]methyl}benzonitrile; 1'-{[1-(3,5-difluonobenzyl)-2-methyl-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin]; 1'-{[1-(2-chlorobenzyl)-2-methyl-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[1-(2-methoxybenzyl)-2-methyl-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[1-(4-methoxybenzyl)-2-methyl-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(1-{[2-(2-methoxyphenyl)-5-methyl-1,3-oxazol-4-il]methyl}-2-methyl-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(1-benzyl-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(6-chloro-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; N,N-dimethyl-2-[3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indole-1-yl]ethanamine; 2-methyl-1-[3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indole-2-yl]butan-1-one; [6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indole-1-yl]acetonitrile; 1'-{[6-chloro-1-(3-fluorobenzoyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(2-fluorobenzoyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(3,5-difluorobenzoyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(2,3-difluorobenzyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(3-fluorobenzyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(2-oxo-2-piperidin-1-ylethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 1'-{[6-chloro-1-(2-morfolin-4-yl-2-oxoethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]-N,N-dimethylacetamide ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-N,N-diethylacetamide ; 1'-{[6-chloro-1-(piperidin-1-ilcarbonyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; tert-butyl [6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)- 1H-indol-1-il]-acetate ; 1'-{[6-chloro-1-(3,5-difluorophenyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 1'-{[6-chloro-1-(3-fluorophenyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-1-(2-fluorophenyl)ethanone ; 1'-[(6-chloro-1-pyridin-2-yl-1H-indol-3-yl)carbonyl]-3H-spirodin[2-benzofuran-1,4'-piperidin] ; 1'-{[6-chloro-1-(pyridin-4-ylmethyl)-1H-indol-3-yl]carbonyl}-3H-spirodin[2-benzofuran-1,4'-piperidin] ; 2-[6-chloro-3-(1'H,3H-spirodin[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]-1-pyridin-2-ylethanone ; 1'-{[6-chloro-1-(pyridin-3-ilmethyl)-1H-indol-3-yl]carbonyl}-3H- spyro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(pyridin-2-ilmethyl)-1H-indol-3-yl]carbonyl}-3H- spyro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(pyrazin-2-ilmethyl)-1H-indol-3-yl]carbonyl}-3H- spyro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(pyrimidin-5-ilmethyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-N,N-dimethylethanamine ; 1'-{[6-chloro-1-(2-oxo-2-piperazin-1-ilethyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 1'-({1-[(4-benzylmorpholin-2-yl)methyl]-6-chloro-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(5-methylisoxazol-3-yl)methyl]-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[2-(4-methylpiperazine-1-yl)-2-oxoethyl)-1H-indol-3-yl}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 4-(1-{1-[2-cyclopropyl-4-methylcyclopenta-1,4-dien-1-yl)methyl]-6-methyl-1H-indol-3-yl}vinyl)-2',3'-dihydrospiro[cyclohexane-1,1'-indine] ; 1'-({6-chloro-1-[1-methyl-1H-imidazol-5-il)methyl]-1H-indol-3-il}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(3-methylisoxazol-5-il)methyl]-1H-indol-3-il}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(1,5-dimethyl-1H-pyrazol-3-il)methyl]-1H-indol-3-il}carbonyl)- 3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(3,5-dimethylisoxazol-4-il)methyl]-1H-indol-3-il}carbonyl)- 3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(2,5-dimethyl-1,3-oxazol-4-yl)methyl]-1H-indol-3-yl}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(3-fluorooxytan-3-yl)methyl]-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(6-chloro-1-{[1-(methoxymethyl)-cyclopropyl]methyl}-1H-indol-3-il)-carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidin] ; (1-{[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-methyl}cyclopropyl)acetonitrile ; 1'-({6-chloro-1-[2-(tetrahydro-2H-pyran-4-il)ethyl]-1H-indol-3-il}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidin] ; tert-butyl 2-{[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]methyl}morpholine-4-carboxylate ; 1'-{[6-chloro-1-(morfolin-2-ylmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] hydrochloride; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]-N-[2-(dimethylamino)ethyl]acetamide; 2-[6-chloro-5-methyl-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-N,N-methylacetamide ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]acetamide ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-N-[2-(methylamino)ethyl]acetamide ; N-(2-aminoethi)-2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]acetamide ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]ethanamine ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-N-methylethanamine ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]-N-methylacetamide ; 1'-{[6-chloro-1-(2-morpholin-2-ilethyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 1'-{[6-chloro-1-(3-morfolin-4-ylpropyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 1'-{[6-chloro-1-(oxiran-2-ylmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidin] ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]ethanol ; 1'-({6-chloro-1-[(2-methylpyridin-4-yl)methyl]-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidin] ; 1'-({6-chloro-1-[(3S)-piperidin-3-ylmethyl]-1H-indol-3-yl}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidin] ; 2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ylcarbonyl)-1H-indol-1-yl]-N-hydroxyethanamine ; 1'-{[6-chloro-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[1-methylpyrolidin-3-yl)methyl]-1H-indol-3-yl}carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(6-chloro-1-{[(3S)-1-methylpiperidin-3-yl]methyl}-1H-indol-3-yl}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-{[6-chloro-1-(pyrrolidin-3-ilmethyl)-1H-indol-3-il]carbonyl}-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-({6-chloro-1-[(2S)-pyrrolidin-2-ilmethyl]-1H-indol-3-il}-carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-[(6-chloro-2-methyl-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] ; 1'-(1,2,3,4-tetrahydropyracino[1,2-a]indol-10-il carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine] hydrochloride; 1'-[(2-methyl-1,2,3,4-tetrahydropyracino[1,2-a]indol-10-il)carbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine]; 1'-[(6-chloro-2-methyl-1H-indol-3-il)carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine]; N-{2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]ethyl}acetamide; N-{2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]ethyl}methenesulfonamide; N-{2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]ethyl}N-methylacetamide; N-{2-[6-chloro-3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-ilcarbonyl)-1H-indol-1-il]ethyl}N-methylmethene sulfonamide ; 1'-[(6-chloro-1-{[(2S)-1-methylpyrrolidin-2-il]methyl}-1H-indol-3-il)carbonyl]- 3H-spiro[2-benzofuran-1,4'-piperidin] ; and 1'-[(6-chloro-1-{[(2R)-1-methylpyrolidin-2-il]methyl}-1H-indol-3-il)-carbonyl]-3H-spiro[2-benzofuran-1,4'-piperidine] 19. A compound with the formula (l-e) according to one of the claims 1 through 4 (chemical formula) (l-e) in which R1, R2, R3, R4 and R6 are as defined in one of the claims 1 through 4. 20. Compounds with the formula (l-e) according to claim 19, where R1 is H, or is C1-6-alkyl which may be selectively substituted by CN, or is sulfonylaryl; or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 6 members, aryl, or heteroaryl with 5 or 6 members which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a 5 or 6-membered heterocycloalkyl, aryl, or a 5 or 6-membered heteroaryl which may be selectively replaced by one or more B groups; R2 is one or more groups of H, halo, C1-6-alkyl; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; R6 is H; B is halo, CN, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively substituted by one or more substituents from a selection of halo, C1-6-alkyl groups which may be substituted by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -S(O)2-C1-6-alkyl, or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 21. Compounds with the formula (l-e) according to claim 19 or 20, where R1 is H, -(CH2)m-Ra, where Ra is a 5 or 6 member heterocycloalkyl, aryl, or 5 or 6 member heteroaryl, or ; -(CH2)m-NRiRii, or , -(CH2)n-(CO)-Rb, where Rb is a 5 or 6 member heterocycloalkyl; R2 is one or more groups of H or halo; R3 is H, or is C1-6-alkyl; R4 is one or more groups of H or halo; R6 is H; Ri and Rii are C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 22. Any compound with the formula (l-e) according to one of the claims 19 through 21, which can be selected from the group consisting of 1'-[(6-chloro-1H-indol-3-yl)carbonyl]spiro[1-benzofuran-3,4'-piperidine]; 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]spiro[1-benzofuran-3,4'-piperidine]; 1'-(1H-indol-3-ylcarbonyl)spiro[1-benzofuran-3,4'-piperidine]; 1'-[(6-chloro-5-fluoro-1H-indol-3-il)carbonyl]spiro[1-benzofuran-3,4'-piperidine] ; 2-[6-chloro-3-(1'H-spiro[1-benzofuran-3,4'-piperidine]-1'-ilcarbonyl)-1H-indol-1-il]-N,N-dimethylethanamine ; 1'-{[6-chloro-1-(2-pyrrolidin-1-ilethyl)-1H-indol-3-il)-1H-indol-3-il]-carbonyl}spiro[1-benzofuran-3,4'-piperidine] ; 3-[6-chloro-3-(1'H-spiro[1-benzofuran-3,4'-piperidine]-1'-ilcarbonyl)-1H-indol-1-il]-N,N-dimethylpropan-1-amine ; 1'-{[6-chloro-1-(2-morpholin-4-ilethyl)-1H-indol-3-il]carbonyl}-spiro[1-benzofuran-3,4'-piperidine] ; 2-[6-chloro-3-(1'H-spiro[1-benzofuran-3,4'-piperidine]-1'-ilcarbonyl)-1H-indol-1-il]-N,N-diethylethanamine ; 1'-({6-chloro-1-[2(1H-pyrrol-1-il)ethyl]-1H-indol-3-il]carbonyl}-spiro[1-benzofuran-3,4'-piperidine] ; and 1'-{[6-chloro-1-(2-oxo-2-piperidine-1-ilethyl)-1H-indol-3-il]carbonyl}-spiro[1-benzofuran-3,4'-piperidine] 23. A compound with the formula (l-f) according to one of the claims 1 through 4 (chemical formula) (l-f) where R1, R2, R3, and R4 are as defined in one of the claims 1 through 4. 24. Compounds with the formula (l-f) according to claim 23, where R1 is H, or is C1-6-alkyl which may be selectively substituted by CN, or is sulfonylaryl; or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 6 members, aryl, or heteroaryl with 5 or 6 members which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a 6-membered heterocycloalkyl, aryl, or a 5 or 6-membered heteroaryl which may be selectively replaced by one or more B groups; R2 is one or more groups of H, halo, C1-6-alkyl; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; B is halo, CN, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively substituted by one or more substituents from a selection of halo, C1-6-alkyl groups which may be substituted by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -S(O)2-C1-6-alkyl, or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 25. Compounds with the formula (l-f) according to claim 23 or 24, where R1 is H; R2 is one or more groups of H or a halo; R3 is H; R4 is one or more groups of H or a halo; including pharmaceutically acceptable salts of these. 26. Any compound with the formula (l-f) according to one of the claims 23 through 25, which can be selected from the group consisting of 5-bromo-1'-(1H-indol-3-ilcarbonyl)spiro[indole-3,4'-piperidine]-2(1H)-one; and 5-bromo-1'-[(6-chloro-1H-indol-3-il)carbonyl]spiro[indole-3,4'-piperidine]-2(1H)-one. 27. A compound with the formula (l-g) according to one of the claims 1 through 4 (chemical formula) (l-g) where R1, R2, R3, and R4 are as defined in one of the claims 1 through 4. 28. Compounds with the formula (l-g) according to claim 27, where R1 is H, or is C1-6-alkyl which may be selectively substituted by CN, or is sulfonylaryl; or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 6 members, aryl, or heteroaryl with 5 or 6 members which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a 6-membered heterocycloalkyl, aryl, or a 5 or 6-membered heteroaryl which may be selectively replaced by one or more B groups; R2 is one or more groups of H, halo, C1-6-alkyl; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; B is halo, CN, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively substituted by one or more substituents from a selection of halo, C1-6-alkyl groups which may be substituted by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -S(O)2-C1-6-alkyl, or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 29. Compounds with the formula (l-g) according to claim 27 or 28, where R1 is H; -(CH2)m-Ra, where Ra is an aryl; R2 is one or more groups of H or a halo; R3 is H; or is C1-6-alkyl; R4 is H; R6 is H; including pharmaceutically acceptable salts of these. 30. Any compound with the formula (l-g) according to one of the claims 27 through 29, which can be selected from the group consisting of (SS,RR)-1'-[(1benzyl-2-methyl-1H-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one; (RS,SR)-1'-[(6-chloro-1H-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one; (RS,SR)-1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-3',5'-dimethyl-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one ; and (1R,3'R,5'S)-1'-[(1-benzyl-2-methyl-1H-indol-3-il)carbonyl]-3',5'-dimethyl-3H-spiro[2-benzofuran-1,4'-piperidin]-3-one 31. A compound with the formula (l-h) according to one of the claims 1 through 4 (chemical formula) (l-h)), where R1, R2, R3, R4, R8 and X are as defined in one of the claims 1 through 4. 32. Compounds with the formula (l-h) according to claim 31, where R1 is H, or is a C1-6-alkyl which may be selectively substituted by CN, or is a sulfonylaryl; or is -(CH2)m-Ra, where Ra is: ORi, CN, NRiRii, C3-6-cycloalkyl, heterocycloalkyl with 3 to 6 members, aryl, or heteroaryl with 5 or 6 members which may be selectively substituted by one or more B groups; Or -(CH2)n-(CO)-Rb, where Rb is: C1-6-alkoxy, NRiRii, a 6-membered heterocycloalkyl, aryl, or a 5 or 6-membered heteroaryl which may be selectively replaced by one or more B groups; R2 is one or more groups of H, halo, C1-6-alkyl; R3 is H, or C1-6-alkyl, or -(CO)-Rc, where Rc is: C1-6-alkyl, -(CH2)n-NRiRii; R4 is one or more groups of H, halo, or C1-6-alkoxy which may be selectively replaced by OH, or two R4 groups may form an oxo or dioxo bridge with the phenyl ring. They are attached to; R8 is H or C1-6-alkyl; X is CH2 or C=O; B is halo, CN, C1-6-alkyl which may be selectively replaced by CN or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, (CRiiiRiv)n-phenyl. Phenyl may be selectively substituted by one or more substituents from a selection of halo, C1-6-alkyl groups which may be substituted by CN or halo, C1-6-alkoxy; Ri and Rii are H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, -(CO)O-C1-6-alkyl, -S(O)2-C1-6-alkyl, or OH; Riii and Riv are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; including pharmacologically acceptable salts of these. 33. Compounds with the formula (l-h) according to claim 31 or 32, where R1 is H; or is -(CH2)n-(CO)-Rb, where Rb is NRiRii; R2 is one or more groups of H or a halo; R3 is H; R4 is H; R8 is H or C1-6-alkyl; X is CH2 or C=O; Ri and Rii are H or C1-6-alkyl; including pharmaceutically acceptable salts of these. 34. Any compound with the formula (l-h) according to one of the claims 31 through 33, which can be selected from the group containing 1'-[(6-chloro-1H-indol-3-il)carbonyl]spiro[isoindole-1,4'-piperidin]-3(2H)-one; 1'-[(6-chloro-1H-indol-3-il)carbonyl]-2-methyl-2,3-dihydrospiro[isoindole-1,4'-piperidin]; 1'-[(6-chloro-1H-indol-3-il)carbonyl]-2,3-dihydrospiro[isoindole-1,4'-piperidin]; and 2-{6-chloro-3-[(3-oxo-2,3-dihydro-1H'-spiro[isoindole-1,4'-piperidine]-1'-il)-carbonyl]-1H-indole-1-il}-N-methylacetamide 35. The process for the preparation of a compound with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h) according to one of the claims 1 through 34, which consists of the reaction of a compound with the formula (ll): (chemical formula) ll with a compound with the formula A-H in order to obtain a compound with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h), where A, R1, R2, and R3 are as defined in one of the claims 1 through 34. 36. The process for the preparation of a compound with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h) according to one of the claims 1 through 34, which consists of the reaction of a compound with the formula (lll): (chemical formula) lll with an electrophilic compound with the formula R1-Y in order to obtain a compound with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h), where R1, R2, and R3 are as defined in one of the claims 1 through 34 and Y is a halo. 37. The process for the preparation of a compound with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h) according to one of the claims 1 through 34, which consists of the reaction of a compound with the formula (lV): (chemical formula) lV with an amine with the formula HNRiRi in order to obtain a compound with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h), where R1, R2, R3, Ri, and Rii are as defined in one of the claims 1 through 34. 38. Compounds with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h) that can be obtained by any of the processes described in Claims 35 through 37. 39. Compounds with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g) or (l-h) according to any of the claims 1 through 34 for use in the prevention or treatment of dysmenorrhea, hypertension, chronic heart failure, vasopressin deficiency, cirrhosis, nephrotic syndrome, obsessive-compulsive disorder, anxiety and depression disorders. 40. A pharmaceutical mixture consisting of one or more compounds with the formulation (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g), or (l-h) according to any one of the claims 1 through 34, and a pharmaceutically acceptable carrier. 41. A pharmaceutical compound under claim 40 which is to be beneficial in the treatment of menstrual pain, hypertension, chronic heart failure, vasopressin deficiency, cirrhosis, nephrotic syndrome, obsessive-compulsive disorder, anxiety disorders, and depression. 42. The use of compounds with the formula (l), (l-a), (l-b), (l-c), (l-d), (l-e), (l-f), (l-g) or (l-h) under any of the claims 1 through 34 for the preparation of pharmaceutical drugs. 43. Under claim 42, the pharmaceutical product is to be used to combat dysmenorrhea, hypertension, chronic heart failure, vasopressin dysfunction, cirrhosis, renal syndromes, obsessive-compulsive disorder, anxiety disorders, and depression.